Pure Global: US AI MedTech & The FDA's Regulatory Chaos

The explosion of AI in MedTech is met with a tangled web of new global regulations. This week, we dissect the latest guidance from the IMDRF and explore the growing divide between regulatory bodies in the US, Europe, and beyond. For AI device makers, the path to market is now filled with more hidden risks than ever. We explore the critical case of "CardioClear AI," a company whose groundbreaking diagnostic tool was recalled. Their self-learning algorithm "drifted" outside its approved limits, creating a regulatory crisis with the FDA. This cautionary tale reveals a common pain point: managing an adaptive AI post-market is a complex challenge that can make or break a company. Key Takeaways: * Why is the IMDRF's new AI guidance a double-edged sword for manufacturers? * What is an FDA Predetermined Change Control Plan and why do most startups get it wrong? * How does the EU's AI Act classify your device, and what new evidence will you need? * Is your AI's "black box" algorithm defensible to regulators? * What are the top three differences between FDA and EU requirements for AI post-market surveillance? * How can you build one technical dossier to streamline multi-market submissions? * What are the key questions to ask before expanding your AI device into Australia or Canada? For more information, contact us at [e-mail], visit https://pureglobal.com/, or explore our free AI tools and medical device database at https://pureglobal.ai/.